Product Description
This is the monoclonal antibody without the tracer. Participants may receive different amounts of BAY3547922 during the study. (Sourced from: https://clinicaltrials.gov/study/NCT06345001)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06345001 |
NCT06345001 | P1 |
Completed |
Hepatocellular Carcinoma |
2025-03-10 |
50% |
2025-04-15 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|